Novo Nordisk announced a 50% price reduction for a semaglutide-based weight-loss medication in the United States. This adjustment targets the rapidly growing obesity management market and is expected to shift competitive dynamics.
The price cut aims to improve medication affordability and broaden patient access. While the move reduces revenue per unit, the company expects higher patient volume to offset the impact.